top of page

Biopharma Daily Stock Updates - 07/22/21

$XBI $127.97 -1.8%

 

Covid Updates

$HGEN -0.1% Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab. source


Pipeline Updates

$CYCN -2.4% Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC). source


$ADVM -2.9% Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema. source


$JAZZ -1.7% National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia. source


$NGM -2.5% NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. source


$EVLO -22.7% Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021. source


$RDHL -1.1% RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex. source


$ADMS -2.0% Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101. source


$RDUS -3.4% Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study. source


$GLYC -2.3% Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients. source


$CBIO -4.4% Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies. source


$RYTM -2.8% Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel. source


$ADAG +4.0% Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab). source


$GBT -3.6% GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD). source


$ARVN +9.0% Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471. source


$MCRB -61.8% Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis. source


$LABP -0.8% Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021.


$ANNX -3.3% Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases . source


$PSTV -1.7% Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial. source


$ERYP +17.0% ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients. source


Financial Updates

$TCON -24.5% TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million. source


$XENT -1.3% Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan. source


 

Posted by FS

0 comments
bottom of page